GERD Market Size to grow by USD 793.85 Mn | North America to emerge as largest market | Technavio

News provided by

Nov 24, 2021, 07:30 ET

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Changing lifestyles of consumers have increased the prevalence of various chronic gastrointestinal diseases such as GERD. This is increasing the use of OTC drugs for the treatment of GERD and acid reflux. Besides, improvements in the economic growth of developing countries such as India and China have resulted in the early detection and effective treatment of various gastrointestinal diseases. In addition, governments across the world are increasing their expenditure on healthcare, which is accelerating R&D activities. Many such factors are expected to create significant opportunities for GERD market vendors during the forecast period.

Attractive Opportunities in GERD Market by Drug Class and Geography - Forecast and Analysis 2021-2025

Technavio estimates the global GERD market size to increase by USD 793.85 million, accelerating a CAGR of 3.01% from 2020 to 2025.

Know the exact market size, growth variance, and future growth opportunities in the global GERD market by purchasing our full report.
Read our Free Sample Before Purchasing

Market Dynamics
The market is driven by factors such as the rising geriatric population and poor lifestyle patterns. However, increased preference for CAM will be hindering the market growth.

The overuse of medicines and dietary supplements will have a positive impact on the growth of vendors. On the other hand, the adverse effects of drugs are expected to reduce the growth potential in the market.

Company Profiles
The GERD market report provides complete insights on key vendors including Alkem Laboratories Ltd., AstraZeneca Plc, Bayer AG, Eisai Co. Ltd., GlaxoSmithKline Plc, Johnson and Johnson Inc., Lupin Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and The Procter and Gamble Co.

Competitive Analysis
The report includes the competitive analysis, which analyzes and evaluates the position of companies based on their industry position score and market performance score. Some of the factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Market Segmentation

By Drug Class, the market is classified as antacid, PPI, H2 receptor antagonist drugs, and pro-kinetic drugs.
By Geography, the market is analyzed across North America, Europe, Asia, and ROW.

The antacid segment generated maximum revenue in the market in 2020. The segment is driven by the easy availability of antacid in the liquid form, as chewing gums or tablets is driving the growth of the segment. In terms of geography, North America will have the largest share of the market. The region currently holds 41% of the global market share. The high prevalence of GERD, increasing preference for OTC medications, and the practice of self-medication among consumers are driving the growth of the GERD market in North America.

Global Gastrointestinal Diseases Therapeutics Market

GERD Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 3.01%
Market growth 2021-2025	USD 793.85 million
Market structure	Fragmented
YoY growth (%)	2.70
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 41%
Key consumer countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading companies, competitive strategies, consumer engagement scope
Companies profiled	Alkem Laboratories Ltd., AstraZeneca Plc, Bayer AG, Eisai Co. Ltd., GlaxoSmithKline Plc, Johnson and Johnson Inc., Lupin Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and The Procter and Gamble Co.
Market Dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio